A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023

References

• Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–16. doi:10.1038/s41568-020-00323-z. Epub 2021/01/242. PubMed PMID: 33483715; PubMed Central PMCID: PMC8353572.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang Z, Ren Z, Li Y. Reactions related to CAR-T cell therapy. Front Immunol. 2021;12:663201. doi:10.3389/fimmu.2021.663201. Epub 2021/05/18. PMID: 33995389; PMCID: PMC8113953.
   PubMedGoogle Scholar
• Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48. doi:10.1016/j.annonc.2020.10.478. Epub 2020/10/26.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang Z, Ren Z, Tang F, Li Y. Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors. Front Immunol. 2021;12:687822. doi:10.3389/fimmu.2021.687822. Epub 2021/06/08. PubMed PMID: 34093592; PubMed Central PMCID: PMCPMC8170155.
   PubMed Web of Science ®Google Scholar
• Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378. doi:10.1126/scitranslmed.abe7378. Epub 2021/04/30. PubMed PMID: 33910979; PubMed Central PMCID: PMCPMC8362330.
   PubMed Web of Science ®Google Scholar
• Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, Montgomery G, Liu B, Roybal KT. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13(591):eabd8836. doi: 10.1126/scitranslmed.abd8836. Epub 2021/04/30. PubMed PMID: 33910981; PubMed Central PMCID: PMCPMC8594452.
   PubMed Web of Science ®Google Scholar
• Qi J, Tsuji K, Hymel D, Burke TR Jr., Hudecek M, Rader C, Peng H. Chemically programmable and switchable CAR-T therapy. Angew Chem Int Ed Engl. 2020;59(29):12178–12185. doi:10.1002/anie.202005432. Epub 2020/04/25.
   PubMed Web of Science ®Google Scholar
• Jan M, Scarfò I, Larson RC, Walker A, Schmidts A, Guirguis AA, Gasser JA, Słabicki M, Bouffard AA, Castano AP, et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021;13(575):eabb6295. doi:10.1126/scitranslmed.abb6295. Epub 2021/01/08. PubMed PMID: 33408186; PubMed Central PMCID: PMCPMC8045771.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wu Y, Allen ME, Pan Y, Kyriakakis P, Lu S, Chang Y-J, Wang X, Chien S, Wang Y. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci Adv. 2020;6(8):eaay9209. doi:10.1126/sciadv.aay9209. Epub 2020/03/05.
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu Y, Huang Z, Wang X, Jin Z, Li J, Limsakul P, Zhu L, Allen M, Pan Y, et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng. 2021;5(11):1336–1347. doi:10.1038/s41551-021-00779-w. Epub 2021/08/14. PubMed PMID: 34385696.
   PubMed Web of Science ®Google Scholar
• Guercio M, Manni S, Boffa I, Caruso S, Di Cecca S, Sinibaldi M, Abbaszadeh Z, Camera A, Ciccone R, Polito VA, et al. Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-Cell malignancies. Front Immunol. 2021;12:755639. doi:10.3389/fimmu.2021.755639. Epub 2021/11/06. PubMed PMID: 34737753; PubMed Central PMCID: PMCPMC8560965.
   PubMed Web of Science ®Google Scholar
• Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947–53. doi:10.1038/s41591-019-0421-7. Epub 2019/04/24. PubMed PMID: 31011207; PubMed Central PMCID: PMCPMC7518381.
   PubMed Web of Science ®Google Scholar
• Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. 2021;27(5):842–50. doi:10.1038/s41591-021-01326-5. Epub 2021/04/24. PubMed PMID: 33888899; PubMed Central PMCID: PMCPMC8451032.
   PubMed Web of Science ®Google Scholar
• Schmidts A, Wehrli M, Maus MV. Toward better understanding and management of CAR-T cell–associated toxicity. Annu Rev Med. 2021;72(1):365–382. doi:10.1146/annurev-med-061119-015600. Epub 2020/08/11.
   PubMedGoogle Scholar
• Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62. doi:10.1038/nrclinonc.2017.148. Epub 2017/09/20. PubMed PMID: 28925994; PubMed Central PMCID: PMCPMC6733403.
   PubMed Web of Science ®Google Scholar
• Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85–96. doi: 10.1038/s41577-021-00547-6. Epub 2021/05/19. PubMed PMID: 34002066.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. doi:10.1016/j.bbmt.2018.12.758. Epub 2018/12/29. PubMed PMID: 30592986.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-9. Epub 2018/06/17.
   PubMed Web of Science ®Google Scholar
• Hong R, Hu Y, Huang H. Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction. Front Immunol. 2021;12:627764. doi:10.3389/fimmu.2021.627764. Epub 2021/03/16.
   PubMed Web of Science ®Google Scholar
• Tedesco V, Mohan C. Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T cell therapy. The Journal Of Immunology. 2021;206(7):1561–1568. doi:10.4049/jimmunol.2001249. Epub 2021/03/12.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978–92. doi:10.1200/jco.21.01992. Epub 2021/11/02. PubMed PMID: 34724386.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, Liu M, Zhou N, Lv J, Tang K, et al. Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43):eaax7969. doi:10.1126/sciimmunol.aax7969. Epub 2020/01/19. PubMed PMID: 31953257.
   PubMed Web of Science ®Google Scholar
• Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol. 2020;146(5):940–8. doi:10.1016/j.jaci.2020.07.025. Epub 2020/08/11. PubMed PMID: 32771558.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, VV R, Locke FL, Maloney DG. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4(7):1432–1439. doi:10.1182/bloodadvances.2019001304. Epub 2020/04/10.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang J, Zhang Z, Wang S, Tang F, Teng M, Li Y. A bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021. Front Immunol. 2022;13:840956. doi:10.3389/fimmu.2022.840956. PubMed PMID: 35371087; PubMed Central PMCID: PMC8971369.
   PubMedGoogle Scholar
• Cooper ID. Bibliometrics basics. J Med Libr Assoc. 2015;103(4):217–228. doi:10.3163/1536-5050.103.4.013. Epub 2015/10/30. PubMed PMID: 26512226; PubMed Central PMCID: PMCPMC4613387.
   PubMed Web of Science ®Google Scholar
• Chen C, Song M, Glanzel W. Visualizing a field of research: a methodology of systematic scientometric reviews. PloS one. 2019;14(10):e0223994. doi:10.1371/journal.pone.0223994. Epub 2019/11/02.
   PubMed Web of Science ®Google Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004;101(Suppl 1):5303–5310. doi:10.1073/pnas.0307513100. Epub 2004/01/16. PubMed PMID: 14724295; PubMed Central PMCID: PMCPMC387312.
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3. Epub 2010/06/30.
   PubMed Web of Science ®Google Scholar
• Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Assoc Inf Sci Technol. 2013;65(2):334–351. doi:10.1002/asi.22968.
   Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44. doi:10.1056/NEJMoa1707447. Epub 2017/12/12. PubMed PMID: 29226797; PubMed Central PMCID: PMCPMC5882485.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. doi:10.1056/NEJMoa1709866. Epub 2018/02/01. PubMed PMID: 29385370; PubMed Central PMCID: PMCPMC5996391.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980. Epub 2018/12/07. PubMed PMID: 30501490.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. doi:10.1056/NEJMoa1709919. Epub 2018/02/01. PubMed PMID: 29385376; PubMed Central PMCID: PMCPMC6637939.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. The Lancet Oncology. 2019;20(1):31–42. doi:10.1016/s1470-2045(18)30864-7. Epub 2018/12/07. PubMed PMID: 30518502; PubMed Central PMCID: PMCPMC6733402.
   PubMed Web of Science ®Google Scholar
• Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood. 2017;130(21):2295–2306. doi:10.1182/blood-2017-06-793141. Epub 2017/09/20. PubMed PMID: 28924019; PubMed Central PMCID: PMCPMC5701525.
   PubMed Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al. Endothelial activation and Blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery. 2017;7(12):1404–1419. doi:10.1158/2159-8290.Cd-17-0698. Epub 2017/10/14. PubMed PMID: 29025771; PubMed Central PMCID: PMCPMC5718945.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–528. doi:10.1016/s0140-6736(14)61403-3. Epub 2014/10/17. PubMed PMID: 25319501; PubMed Central PMCID: PMCPMC7065359.
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48. doi:10.1038/s41591-018-0036-4. Epub 2018/05/29. PubMed PMID: 29808007.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell all patients. Journal Of Clinical Investigation. 2016;126(6):2123–2138. doi:10.1172/jci85309. Epub 2016/04/26. PubMed PMID: 27111235; PubMed Central PMCID: PMCPMC4887159.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. doi:10.1056/NEJMoa1407222. Epub 2014/10/16. PubMed PMID: 25317870; PubMed Central PMCID: PMCPMC4267531.
   PubMed Web of Science ®Google Scholar
• Ma D, Yang B, Guan B, Song L, Liu Q, Fan Y, Zhao L, Wang T, Zhang Z, Gao Z, et al. A bibliometric analysis of pyroptosis from 2001 to 2021. Front Immunol. 2021;12:731933. doi:10.3389/fimmu.2021.731933. Epub 2021/09/07. PubMed PMID: 34484243; PubMed Central PMCID: PMCPMC8416445.
   PubMed Web of Science ®Google Scholar
• Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20. doi:10.1186/s12943-023-01723-z. Epub 2023/02/01. PubMed PMID: 36717905; PubMed Central PMCID: PMCPMC9885707.
   PubMed Web of Science ®Google Scholar
• Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430–42. doi:10.1182/blood.2022017414. Epub 2023/03/30. PubMed PMID: 36989488; PubMed Central PMCID: PMCPMC10329191.
   PubMed Web of Science ®Google Scholar
• Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2023;16(1):34. doi:10.1186/s13045-023-01427-3. Epub 2023/04/06. PubMed PMID: 37020231; PubMed Central PMCID: PMCPMC10074659.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed/refractory all. Clin Cancer Res. 2023;29(4):742–53. doi:10.1158/1078-0432.Ccr-22-2038. Epub 2022/10/19. PubMed PMID: 36255386.
   PubMed Web of Science ®Google Scholar
• Raghunandan S, Pauly M, Blum WG, Qayed M, Dhodapkar MV, Elkhalifa M, Watkins B, Schoettler M, Horwitz E, Parikh S, et al. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. J Immunother Cancer. 2023;11(5):e006684. doi:10.1136/jitc-2023-006684. Epub 2023/05/04. PubMed PMID: 37137553; PubMed Central PMCID: PMCPMC10163502.
   PubMed Web of Science ®Google Scholar
• Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, López-Corral L, Hernani R, et al. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29(7):430–437. doi:10.1016/j.jtct.2023.04.001. Epub 2023/04/10. PubMed PMID: 37031746; PubMed Central PMCID: PMCPMC10330552.
   PubMedGoogle Scholar
• Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales M-A, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023;29(7):1710–17. doi:10.1038/s41591-023-02404-6. Epub 2023/07/04. PubMed PMID: 37400640.
   PubMed Web of Science ®Google Scholar
• Pensato U, Amore G, Muccioli L, Sammali S, Rondelli F, Rinaldi R, D’Angelo R, Nicodemo M, Mondini S, Sambati L, et al. CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and assessment in lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study. J Neurol. 2023;270(5):2659–2673. doi:10.1007/s00415-023-11595-4. Epub 2023/03/05. PubMed PMID: 36869888.
   PubMed Web of Science ®Google Scholar
• Leclercq-Cohen G, Bacac M, Klein C. Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS). Expert Opin Biol Ther. 2023;23(3):223–225. Epub 2023/01/12 PubMed PMID: 36629122. doi: 10.1080/14712598.2023.2166786.
   PubMed Web of Science ®Google Scholar
• Harris K, LaBelle JL, Bishop MR. Current status of CAR T cell therapy for leukemias. Curr Treat Options Oncol. 2021;22(7):62. doi:10.1007/s11864-021-00859-8. Epub 2021/06/08. PubMed PMID: 34097135.
   PubMed Web of Science ®Google Scholar
• Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2021;46(1):100826. doi:10.1016/j.currproblcancer.2021.100826. Epub 2022/01/12. PubMed PMID: 35012754.
   PubMed Web of Science ®Google Scholar
• Haslauer T, Greil R, Zaborsky N, Geisberger R. CAR T-cell therapy in hematological malignancies. Int J Mol Sci. 2021;22(16):8996. doi:10.3390/ijms22168996. Epub 2021/08/28.
   PubMed Web of Science ®Google Scholar
• Viardot A, Sala E. Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. Expert Opin Investig Drugs. 2021;30(7):773–784. doi:10.1080/13543784.2021.1928074. Epub 2021/05/18.
   PubMed Web of Science ®Google Scholar
• Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for all. Bone Marrow Transplant. 2021;56(3):552–566. Epub 2020/11/25. PubMed PMID: 33230186; PubMed Central PMCID: PMCPMC8592274.
   PubMed Web of Science ®Google Scholar
• Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-Cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021;22(14):7652. doi:10.3390/ijms22147652. Epub 2021/07/25.
   PubMed Web of Science ®Google Scholar
• Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367. doi:10.1186/s13046-021-02148-6. Epub 2021/11/20.
   PubMed Web of Science ®Google Scholar
• Akhoundi M, Mohammadi M, Sahraei SS, Sheykhhasan M, Fayazi N. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cellular Oncology (Dordrecht). 2021;44(3):495–523. doi:10.1007/s13402-021-00593-1. Epub 2021/03/25. PubMed PMID: 33759063.
   PubMed Web of Science ®Google Scholar
• Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, Wolters PL, Steinberg SM, Baker EH, Delbrook CP, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-all. J Clin Oncol. 2021;39(15):1650–9. doi:10.1200/jco.20.02262. Epub 2021/03/26. PubMed PMID: 33764809; PubMed Central PMCID: PMCPMC8274806.
   PubMed Web of Science ®Google Scholar
• Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295–1312. doi:10.1002/ajh.26301. Epub 2021 Aug 13. PMID: 34310745; PMCID: PMC9290945.
   PubMed Web of Science ®Google Scholar
• Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70. doi:10.1186/s13045-020-00905-2. Epub 2020/06/07.
   PubMed Web of Science ®Google Scholar
• Zhao J, Song Y, Liu D. Recent advances on blinatumomab for acute lymphoblastic leukemia. Exp Hematol Oncol. 2019;8(1):28. doi:10.1186/s40164-019-0152-y. Epub 2019/11/12.
   PubMed Web of Science ®Google Scholar
• Stein A, Franklin JL, Chia VM, Arrindell D, Kormany W, Wright J, Parson M, Amouzadeh HR, Choudhry J, Joseph G. Benefit–risk assessment of blinatumomab in the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Drug Safety. 2019;42(5):587–601. doi:10.1007/s40264-018-0760-1. Epub 2018/12/20.
   PubMed Web of Science ®Google Scholar
• Jain T, Litzow MR. Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:2040620719899897. doi:10.1177/2040620719899897. Epub 2020/02/06.
   Web of Science ®Google Scholar
• Chen C. Science mapping: a systematic review of the literature. J Data Inf Sci. 2017;2(2):1–40. doi:10.1515/jdis-2017-0006.
   Google Scholar
• Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149–58. doi:10.1182/blood.2019001463. Epub 2019/11/08. PubMed PMID: 31697826; PubMed Central PMCID: PMCPMC6908832.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–28. doi:10.1200/jco.19.02104. Epub 2020/05/14. PubMed PMID: 32401634; PubMed Central PMCID: PMCPMC7499611.
   PubMed Web of Science ®Google Scholar
• Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(Suppl 1):48–52. doi:10.1002/hon.2595. Epub 2019/06/13. PubMed PMID: 31187535.
   PubMed Web of Science ®Google Scholar
• Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng X-Q, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543–51. doi:10.1073/pnas.1819745116. Epub 2019/04/17. PubMed PMID: 30988175; PubMed Central PMCID: PMCPMC6510991.
   PubMed Web of Science ®Google Scholar
• Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–24. doi:10.1182/bloodadvances.2020003092. Epub 2020/11/05. PubMed PMID: 33147337; PubMed Central PMCID: PMCPMC7656920.
   PubMed Web of Science ®Google Scholar
• Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-all. Blood. 2019;134(26):2361–8. doi:10.1182/blood.2019001641. Epub 2019/10/28. PubMed PMID: 31650176; PubMed Central PMCID: PMCPMC6933289.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, et al. Axicabtagene Ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095–106. doi:10.1200/jco.19.02103. Epub 2020/07/16. PubMed PMID: 32667831; PubMed Central PMCID: PMCPMC7499617.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, et al. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma. Journal Of Clinical Investigation. 2019;129(6):2210–2221. doi:10.1172/jci126397. Epub 2019/03/22. PubMed PMID: 30896447; PubMed Central PMCID: PMCPMC6546468.
   PubMed Web of Science ®Google Scholar
• Gong N, Han X, Xue L, El-Mayta R, Metzloff AE, Billingsley MM, Hamilton AG, Mitchell MJ. In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nat Mater. 2023. doi:10.1038/s41563-023-01646-6. Epub ahead of print. PMID: 37696939.
   Web of Science ®Google Scholar
• Li X, Gong N, Tian F, Zhang S, Zhang Y, Wang Y, Qing G, Wang Y, Li F, Xu Y, et al. Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat Biomed Eng. 2023;7(9):1129–1141. doi:10.1038/s41551-023-01084-4. Epub 2023/09/12. PubMed PMID: 37696984.
   PubMed Web of Science ®Google Scholar
• Butt OH, Zhou AY, Ances BM, DiPersio JF, Ghobadi A. A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. Front Neurol. 2023;14:1110647. doi:10.3389/fneur.2023.1110647. Epub 2023/03/03. PubMed PMID: 36860569; PubMed Central PMCID: PMCPMC9969296.
   PubMed Web of Science ®Google Scholar
• De Matteis S, Dicataldo M, Casadei B, Storci G, Laprovitera N, Arpinati M, Maffini E, Cortelli P, Guarino M, Vaglio F, et al. Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity. Front Immunol. 2022;13:1058126. doi:10.3389/fimmu.2022.1058126. Epub 2023/02/03. PubMed PMID: 36726971; PubMed Central PMCID: PMCPMC9886226.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002–14. doi:10.1056/NEJMoa2213614. Epub 2023/02/11. PubMed PMID: 36762851.
   PubMed Web of Science ®Google Scholar
• Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, Malik S, Nath R, Anwer F, Cruz JC, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422–9. doi:10.1038/s41591-022-02182-7. Epub 2023/01/24. PubMed PMID: 36690811.
   PubMedGoogle Scholar
• Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, Xu L, Gao F, Wang Y, Wang F, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12(1):44. doi:10.1186/s40164-023-00402-5. Epub 2023/05/09. PubMed PMID: 37158921; PubMed Central PMCID: PMCPMC10165782.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, et al. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811–22. doi:10.1016/s1470-2045(23)00246-2. Epub 2023/07/07. PubMed PMID: 37414012.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang J, Huang B, Zhang Z, Wang S, Tang F, Teng M, Li Y. Special Chimeric Antigen Receptor (CAR) modifications of T cells: a review. Front Oncol. 2022;12:832765. doi:10.3389/fonc.2022.832765. Epub 2022/04/09. PubMed PMID: 35392217; PubMed Central PMCID: PMCPMC8981721.
   PubMed Web of Science ®Google Scholar